ライフサイエンスコーパス: cervical cytology

1 d again in 2001 from 1,775 women with normal cervical cytology.

2 tem terminology for reporting the results of cervical cytology.

3 y and correlated the results with concurrent cervical cytology.

4 ound in up to 40% of young women with normal cervical cytology.

5 avirus (HPV) types, are more protective than cervical cytology.

6 Cervical cytology abnormality following either HPV vacci

7 ine effectiveness included rates of abnormal cervical cytology and genital warts.

8 In this observational study, all cervical cytology and HPV testing reports from January 1

9 coplasma genitalium and its association with cervical cytology and other correlates, we recruited 350

10 Women were assessed for HPV infection by cervical cytology and self-obtained cervicovaginal sampl

11 -16 variants at a high viral load), abnormal cervical cytology, and SIL.

12 DNA, using cervical samples, and did yearly cervical cytology assessments.

13 , 88%-94%]) HIV-uninfected women with normal cervical cytology at enrollment.

14 men and 279 HIV-uninfected women with normal cervical cytology at their enrollment in a multi-institu

15 Cervical cytology between July 2007 and July 2014 was te

16 cted in 15 of 37 (40.5%) women with abnormal cervical cytology but in only 4 of 35 (11.4%) women with

17 of residual specimens collected for routine cervical cytology can help identify those who have under

18 t testing for human papillomavirus (HPV) and cervical cytology (co-testing) is an approved alternativ

19 A total of 11 017 cases of cervical cytology complemented with data on hrHPV testin

20 rkov model as part of a systematic review of cervical cytology conducted at the Duke University Evide

21 Routine clinical data included anal and cervical cytology, demographic/behavioral data, and high

22 nique, the new Bethesda system for reporting cervical cytology findings, and several recent professio

23 5%) in the number of women with precancerous cervical cytology findings.

24 atively low HPV vaccine coverage, the PPV of cervical cytology for CIN 2 or more severe diagnosis was

25 PPV of abnormal cervical cytology for risk of cervical intraepithelial n

26 primary cervical screening, as an adjunct to cervical cytology for the management of low grade abnorm

27 erature on type-specific HPV distribution by cervical cytology grade and document that alpha-9 phylog

28 IN), which resembled human CIN by endoscopy, cervical cytology, histology, and immunohistochemistry.

29 Regular cervical cytology is critical due to a recognized increa

30 The standard for reading cervical cytology is for a cytoscreener to manually sear

31 The routine practice of cervical cytology is limited by problems of false negati

32 A tests have been approved only for abnormal cervical cytology management and as an adjunct to cervic

33 According to The Bethesda System, cervical cytology necessitates further classification of

34 ho were healthy, with no history of abnormal cervical cytology, no previous abnormal cervical biopsy

35 reflex HPV DNA testing, a strategy of repeat cervical cytology or delayed HPV testing costs more but

36 m 3 years to 5 years among those with normal cervical cytology (Pap test) results who test negative f

37 result, a combination of HPV genotyping and cervical cytology (Papanicolaou testing) can identify th

38 prove health; strong indirect evidence links cervical cytology programmes to declines in cervical can

39 The detection rate for an abnormal cervical cytology result during the observation period w

40 The risk for an abnormal cervical cytology result was lower among vaccinated vs u

41 ients aged 21 to 35 years who had at least 1 cervical cytology result within a single health system b

42 demographics, clinic type, abnormal baseline cervical cytology result, and baseline Chlamydia screeni

43 Seven women reported abnormal cervical cytology results after transplantation.

44 rated vaccine effectiveness against abnormal cervical cytology results.

45 helial neoplasia (CIN2+) in a total of 8,610 cervical cytology samples from the ARTISTIC population-b

46 Here we analyze 1941 cervical cytology samples, which contain a mixture of ho

47 gies for cervical cytology screening, proper cervical cytology sampling technique, the new Bethesda s

48 le adults aged 40 to 74 years; and triennial cervical cytology screening among female adults aged 21

49 l recent professional society guidelines for cervical cytology screening and management of cytologic

50 We estimate that cervical cytology screening of all women aged 55-79 year

51 We sought to quantify the efficacy of cervical cytology screening to reduce death from this di

52 ny HIV-infected women do not undergo routine cervical cytology screening, however, and there are curr

53 men, the development of new technologies for cervical cytology screening, proper cervical cytology sa

54 ugh 20 years of age and underwent subsequent cervical cytology screening.

55 cal cytology management and as an adjunct to cervical cytology screening.

56 l copy number changes directly in thin-layer cervical cytology slides by fluorescence in situ hybridi

57 s of the Inv2 test in the screening of ASCUS cervical cytology specimens and correlates the results o

58 population-based stratified sample of 59 664 cervical cytology specimens from women residing in New M

59 more often than in HIV-seropositive abnormal cervical cytology than uninfected ones and were more lik

60 V-16-infected women with normal and abnormal cervical cytologies to obtain evidence of active infecti

61 The success of screening tools such as cervical cytology to reduce mortality has spurred signif

62 R HPV infections; the prevalence of abnormal cervical cytology was 38% among women who were HR HPV-po

63 Colposcopic directed biopsies and cervical cytology were performed at week 26 and 52.

64 Colposcopic-directed biopsies and cervical cytology were performed at weeks 26 and 52.